Akcea is a biopharmaceutical company that develops RNA-targeted antisense therapeutics for the treatment of cardiometabolic lipid disorders. Akcea was founded in 2015. Akcea's headquarters is located in Boston, Massachusetts, USA 02210.
Akcea's CEO, ... Akcea's CEO, Damien McDevitt, currently has an approval
rating of 75%. Akcea's primary competitors are Alnylam, Eidos & Amryt Pharma.
There have been no acquisitions found related to Akcea
Recent investment data cannot be found related to Akcea